Stem cell research.
How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in […]
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
A new stem cells for ALS treatment trial represents a big step forward. It’s early days still but this trial shows feasibility and provides a helpful foundation for moving forward. It also highlights challenges. The work is from a team led by Clive Svendsen. Stem cells for ALS treatment trial Here’s the study. Transplantation of
There was a time when I thought transdifferentiation based approaches might quickly move into clinical trials. Then things kind of cooled off. We didn’t see many papers reporting methods to transdifferentiate cells. I still think that this technology, sometimes called direct reprogramming, has major potential. A new paper on making human brain cells this way got
Paper sparks renewed interest in transdifferentiation & clinical potential Read More »
The big news of the week was the big FDA stem cell in court by Judge Jesus Bernal here in California, who ruled in favor of a chain of stem cell clinics called Cell Surgical Network. The FDA had been seeking an injunction against the clinics. I believe the ruling was founded in part on
Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics Read More »
I have a soft spot for fibroblasts, perhaps because one of the first immortalized cell lines I ever grew was NIH3T3. These are mouse fibroblasts that have been immortalized. They are very useful for a variety of experiments. I used them to study an oncogene called E2A-PBX1. Experience with fibroblasts including 3T3s I was amazed
Weekly reads: fibroblasts, gene-editing, Mitalipov, personhood, embryos Read More »
I took a cross-country road trip earlier this month that was pretty amazing and barely thought about stem cell research for the first time in years. We did run across one stem cell clinic in Florida by accident. I’ll write about that trip soon, but first we have our weekly reads including some very cool
Weekly stem cell reads: space, plagiarism, HIV, diabetes, more Read More »
I’ve been following the stem cells for COVID arena for more than two years. During this time researchers have launched scores of trials. A few have been published including a new one. It’s been a wild ride that at times has included politics and an odd cast of characters. There was Rick Perry and also Rudy Guiliani getting
A close look at new stem cells for COVID trial pub Read More »
Eight years ago two new Nature papers broke on the scene reporting supposed STAP cells with one of the senior authors, Charles Vacanti of Harvard, most well known previously for making the so-called “Vacanti mouse” along with his brother Joseph. The Vacanti mouse had a bioengineered human ear growing on its back. While STAP cells
Recommended reads: Dux, 3D printed ear brings Vacanti mouse to mind, AMD, more Read More »
The Pink Sheet just broke the story that the FDA may change up its oversight of the cell therapy space. This possible shift could drop the oversight bar somewhat for certain products. Most likely it’d be those with lower anticipated risks. The Pink Sheet piece by Sue Sutter is titled US FDA To Explore New Regulatory Pathways
One size doesn’t fit all? FDA may soften some cell therapy regs Read More »
The regular emails and phone calls I get from patients asking questions about stem cell therapy are a powerful reminder of the fact that research in our field can be very personal. Sometimes individuals who receive experimental stem cell therapy (or other cell therapies) and seem to have a positive outcome can end up becoming
Overplaying N=1 in the stem cell therapy world Read More »